Boston Scientific Becomes Third US TAVR Competitor With Lotus Edge Approval

 
• By Reed Miller

The US FDA approved Boston Scientific's Lotus Edge transcatheter aortic valve for patients who would be at high risk with surgical valve replacement. Unlike competing TAVR systems from Medtronic and Edwards, Lotus Edge can be repositioned or recaptured after it has been deployed.

New competition business concept with a chess pawn punching and destroying competitors as two king pieces with hidden red boxing gloves as a metaphor for innovative corporate attack strategy. - Illustration
• Source: shutterstock.com

More from Approvals

More from Policy & Regulation